Atrium Therapeutics, Inc.

NASDAQ:RNA

Biotechnology

Healthcare
$6.98 +1.28%

+$0.16 today

Market cap
$150.57M
Beta
0.42
P/E (TTM)
-3.3
EPS (TTM)
-$3.78
52W Low $11.40High $16.77

Volume 0.23M

Average 0.35M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$41.13M

FY 2025 · Annual

Investing Cash Flow

-$1.45M

FY 2025 · Annual

Financing Cash Flow

$42.57M

FY 2025 · Annual

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$49.5M
+ D&A$323.0K
+ Stock-Based Comp$7.7M
- Deferred Tax-$142.0K
- Working Capital-$200.0K
+ Other Non-Cash$712.0K
= Operating Cash Flow-$41.1M
- Capex-$1.4M
= Free Cash Flow-$42.6M

Analysis

FY2025 free cash flow is -$42.6M. FCF conversion is 86.0% of net income. Operating cash flow was -$41.1M, with capex of -$1.4M. The largest bridge item is Stock-Based Comp at $7.7M.

Competitors

Peer companies in the same sector

Health

No competitor data available.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 12, 2026
10-QQuarterly reportNov 12, 2026
8-KCurrent reportNov 2, 2026
8-KCurrent reportOct 27, 2026
8-K/A8-K/A filingOct 9, 2026

Does RNA generate free cash flow?

Atrium Therapeutics, Inc. (RNA) generated -$42.57M of free cash flow in fiscal 2025.

How much operating cash flow does RNA produce?

Operating cash flow was -$41.13M, before capital expenditures of $1.45M.